EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pharmacielo Ltd (PCLO) fair value: what the stock is really worth

We calculate from audited financials what Pharmacielo Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · CA · ISIN CA71716K1012

PL Thin data Jun 23, 2026

Pharmacielo Ltd

PCLO · V

Low PriorityFair Value upside is limited and quality is weak.

·Fair value C$0.0600 · Fairly valued (+9%)
!Quality 40/100
!Mixed Growth (revenue 5y +34.6 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/5)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
Watch Pharmacielo Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$1.67 C$0.0350 Fair Value C$0.0600 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range C$0.0350 – C$1.67 · fair‑value band C$0.0500 – C$0.0800 · the C$0.0550 price screens below the C$0.0600 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Pharmacielo in your weekly email

Every Wednesday you see whether Pharmacielo is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada.

Show more

PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. The company's products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies. PharmaCielo Ltd. is headquartered in Toronto, Canada.

Stock analysis

Pharmacielo Ltd (PCLO) currently trades at C$0.0550, while our model-based Fair Value estimate is C$0.0600, implying the stock looks roughly 8.3% fairly valued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: C$0.0500 (bear) to C$0.0800 (bull), the price of C$0.0550 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Pharmacielo Ltd reported revenue of C$3.5M in FY2024 versus C$2.7M in FY2020, a compound +7.0%/yr. Reported net income was −C$9.1M in FY2024.

Key figures

Market cap C$19.7M (≈ $14.0M) · P/S ratio 11.3 · EPS (TTM) C$−0.0500 · Net margin −266% · Return on equity −3,013% · Return on assets (EBIT) −57.2% · Operating margin 262% · Revenue (TTM) C$1.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 59% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 9%, PCLO screens cheaper than that median.

Notify me when PCLO reaches fair value

Put PCLO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 40/100

Of which business quality 34 · Market factors (momentum, volatility) 46

Profitability 3
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 1
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 49
Calm price path (market factor)
Momentum 49
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 28
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+125.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,316.1% (2019) → −140.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Watch PCLO, get fair value alerts →

Compare Pharmacielo Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +9% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −14% · Bottom 25%
Growth and dividend
Revenue growth −46% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 7.99× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)45 · sector 15
FUTURE (revenue growth)0 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmacielo Ltd · Fair Value
C$0.0600 +8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pharmacielo Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PCLO

Frequently asked questions

Is Pharmacielo Ltd (PCLO) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of C$0.0600 versus a price of C$0.0550, about +9% upside (fairly valued).
What is the fair value of PCLO?
Our model-based fair value for Pharmacielo Ltd is C$0.0600 (as of Jun 23, 2026), built from audited fundamentals. The current price: C$0.0550.
What is the quality score of PCLO?
Pharmacielo Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmacielo Ltd (PCLO)?
Our model-based price target is the fair value of C$0.0600 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario C$0.0500, optimistic scenario C$0.0800. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmacielo Ltd stock forecast for 2026?
Our models put fair value at C$0.0600, about +9% upside versus a price of C$0.0550 (fairly valued). Cautious scenario C$0.0500, optimistic scenario C$0.0800. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmacielo Ltd (PCLO)?
Pharmacielo Ltd reported trailing-twelve-month revenue of about C$1.8M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Pharmacielo Ltd (PCLO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmacielo Ltd it is C$0.0600 per share (as of Jun 23, 2026), against a price of C$0.0550. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Pharmacielo Ltd stock overvalued or undervalued in 2026?
As of Jun 23, 2026, PCLO trades below its calculated fair value: price C$0.0550, fair value C$0.0600, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCLO?
No. The price is what the market pays today (C$0.0550); the fair value is what the company's own numbers justify (C$0.0600). For Pharmacielo Ltd the two are C$0.0050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmacielo Ltd worth?
The market values Pharmacielo Ltd at about C$19.7M (market capitalisation, as of Jun 23, 2026). Per share that is C$0.0550; our models calculate a fair value of C$0.0600 per share.
What do the bullish and bearish scenarios say about PCLO?
Our models span a range for Pharmacielo Ltd: cautious scenario C$0.0500, base C$0.0600, optimistic C$0.0800 per share (as of Jun 23, 2026, price C$0.0550). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmacielo Ltd (PCLO)?
Balance-sheet figures for Pharmacielo Ltd (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is PCLO from its 52-week high?
Pharmacielo Ltd trades at C$0.0550, about 59% below its 52-week high of C$0.1350 and 38% above the low of C$0.0400 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.0600 is for.
Which stocks are comparable to Pharmacielo Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmacielo Ltd stock attractive at the current price?
The data as of Jun 23, 2026: price C$0.0550, calculated fair value C$0.0600 (+9%), Quality Score 40/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PCLO calculated?
We run Pharmacielo Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.0600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Pharmacielo Ltd currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmacielo Ltd (PCLO)?
The closing price on Sep 23, 2026 was C$0.0550. Our model-based fair value is C$0.0600, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmacielo Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pharmacielo Ltd

How large is the market capitalisation of Pharmacielo Ltd (PCLO)?
The market capitalisation of Pharmacielo Ltd is C$19.7M (≈ $14.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmacielo Ltd (PCLO)?
The price-to-sales ratio of Pharmacielo Ltd is 11.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmacielo Ltd (PCLO)?
Earnings per share at Pharmacielo Ltd are C$−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pharmacielo Ltd (PCLO)?
The net margin of Pharmacielo Ltd is −266% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmacielo Ltd (PCLO)?
The return on equity (ROE) of Pharmacielo Ltd is −3,013% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmacielo Ltd (PCLO)?
On an EBIT basis the return on assets of Pharmacielo Ltd is −57.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmacielo Ltd (PCLO)?
The operating margin of Pharmacielo Ltd is 262% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmacielo Ltd (PCLO)?
Revenue at Pharmacielo Ltd is growing −46.2% versus a year earlier (3y avg +21.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmacielo Ltd (PCLO) generate?
The free cash flow of Pharmacielo Ltd is −C$2.0M (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmacielo Ltd (PCLO) carry?
The net debt of Pharmacielo Ltd is C$20.4M (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pharmacielo Ltd in the live analysis

One click puts Pharmacielo Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.